Genetic variation is critical to allow populations to adapt to current and future environmental stresses. Read Pursuit piece by Bio21's Ary Hoffmann...

Professor Leann Tilley and Dr Stanley Xie from the Bio21 Institute are working with experts from the Japanese company, Takeda Pharmaceuticals, and Swiss-based foundation, Medicines for Malaria Venture (MMV), in a double-pronged effort to develop new antimalarial drugs.  

Melbourne Dental School Head of School Mike Morgan, CSL Senior Vice President of Research Andrew Nash, University of Melbourne Vice-President (Enterprise) Doron Ben-Meir, COHR CEO & Director of Research Eric Reynolds, Member for Higgins Katie Allen and Brandon Capital Investment Manager Ingmar Wahlqvist at the launch of Denteric.

New research was published today [Cell Host and Microbe, 11 September] that shows how an important group of human pathogens cause disease, opening up fresh avenues for much needed therapies.

Congratulations to Bio21's Leann Tilley and David Ascher, who have received NHMRC Development and Investigator grants respectively.

An exciting new microscope has been installed in the Biochemistry and Molecular Biology Node of the Biological Optical Microscopy Platform at the Bio21 Institute, 28 August 2019.

Read about Justine Mintern, Biochemistry and Molecular Biology, Head of Vaccine Biology Lab